Inmune Bio Stock Investor Sentiment

INMB Stock  USD 8.17  0.22  2.77%   
About 63% of all INmune Bio's investors are looking to take a long position. The analysis of the overall investor sentiment regarding INmune Bio suggests that some traders are interested. The current market sentiment, together with INmune Bio's historical and current headlines, can help investors time the market. In addition, many technical investors use INmune Bio stock news signals to limit their universe of possible portfolio assets.
  

INmune Bio Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards INmune Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
48.6%
53.9%
47.7%
52.6%
53.3%
46.9%
51.6%
47.5%
47.9%
52.8%
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

INmune Bio Maximum Pain Price Across April 17th 2025 Option Contracts

INmune Bio's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of INmune Bio close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of INmune Bio's options.
Max Pain 10Calls PricePuts Price100%
2 days ago at www.macroaxis.com         
Acquisition by Lowdell Mark William of 140000 shares of INmune Bio at 5.05 subject to Rule 16b-3
Macroaxis News
few days ago at www.macroaxis.com         
Acquisition by Baracchini Edgardo Jr of 35000 shares of INmune Bio subject to Rule 16b-3
Macroaxis News
six days ago at news.google.com         
INmune Bio Reports Promising Phase III Trial Results - TipRanks
Google News at Macroaxis
over a week ago at finance.yahoo.com         
Why INmune Bio, Inc. is Skyrocketing So Far in 2025
Yahoo News
over a week ago at simplywall.st         
Is INmune Bio A Risky Investment?
Simply Wall St News at Macroaxis
over two weeks ago at finance.yahoo.com         
INmune Bio, Inc. most popular amongst individual investors who own 36 percent of the shares, institu...
Yahoo News
over three weeks ago at thelincolnianonline.com         
INmune Bio, Inc. Short Interest Update
news
over three weeks ago at thelincolnianonline.com         
INmune Bio Price Target Raised to 23.00 at Scotiabank
news
over three weeks ago at globenewswire.com         
INmune Bio Opens Phase II in High Dose Cohort of INKmune Trial in Prostate Cancer
Macroaxis News: globenewswire.com
over three weeks ago at finance.yahoo.com         
INmune Bio Opens Phase II in High Dose Cohort of INKmune Trial in Prostate Cancer
Yahoo News
over three weeks ago at gurufocus.com         
INmune Bio Opens Phase II in High Dose Cohort of INKmune Trial
Gurufocus Stories at Macroaxis
over three weeks ago at thelincolnianonline.com         
INmune Bio Inc. Discloses New Investor and Webinar PresentationsOn February 10, 2025, INmune Bio Inc...
news
over three weeks ago at finance.yahoo.com         
INmune Bio Announces Plan to Submit FDA Biologics License Application Seeking Approval of CORDStrom ...
Yahoo News
over three weeks ago at gurufocus.com         
INmune Bio Announces Plan to Submit FDA Biologics License Application Seeking Approval of ...
Gurufocus Stories at Macroaxis
over three weeks ago at globenewswire.com         
INmune Bio Announces Plan to Submit FDA Biologics License Application Seeking Approval of CORDStrom ...
Macroaxis News: globenewswire.com
Far too much social signal, news, headlines, and media speculation about INmune Bio that are available to investors today. That information is available publicly through INmune media outlets and privately through word of mouth or via INmune internal channels. However, regardless of the origin, that massive amount of INmune data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of INmune Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of INmune Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to INmune Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive INmune Bio alpha.

INmune Bio Performance against Dow Jones

 Price Growth (%)  
JavaScript chart by amCharts 3.21.15123456789101112Dec2025Feb -20020406080100
JavaScript chart by amCharts 3.21.15INmune Bio INmune Bio Dividend Benchmark Dow Jones Industrial
       Timeline  
1
Acquisition by Allen Marcia of 32500 shares of INmune Bio at 5.05 subject to Rule 16b-3
12/20/2024
2
Acquisition by Lowdell Mark William of 14423 shares of INmune Bio at 8.32 subject to Rule 16b-3
12/31/2024
3
Acquisition by Moss David J of 160000 shares of INmune Bio at 9.92 subject to Rule 16b-3
01/24/2025
4
INmune Bio Rating Increased to Strong-Buy at RODMANRENSHAW - MarketBeat
01/29/2025
5
Acquisition by Xencor Inc of 192533 shares of INmune Bio at 17.14 subject to Rule 16b-3
01/30/2025
6
Acquisition by Schroeder Timothy J of 12500 shares of INmune Bio at 9.92 subject to Rule 16b-3
01/31/2025
7
Why INmune Bio Inc Is Skyrocketing So Far In 2025 - Yahoo Finance
02/03/2025
8
Why INmune Bio Inc Is Skyrocketing So Far In 2025
02/04/2025
9
INmune Bio Announces Plan to Submit FDA Biologics License Application Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa
02/10/2025
10
INmune Bio Opens Phase II in High Dose Cohort of INKmune Trial in Prostate Cancer
02/12/2025
11
Acquisition by Baracchini Edgardo Jr of 35000 shares of INmune Bio subject to Rule 16b-3
03/05/2025
12
Acquisition by Lowdell Mark William of 140000 shares of INmune Bio at 5.05 subject to Rule 16b-3
03/07/2025

Complementary Tools for INmune Stock analysis

When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Bonds Directory
Find actively traded corporate debentures issued by US companies
News Freq…Investor S…